



ChemoCentryx, Inc.
 Investor Relations Department
 850 Maude Avenue
 Mountain View, CA 94043
 United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: CCXI

Last Trade:	8.75
Trade Time:	4:00 PM ET Jan 23, 2018
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	5.42 - 10.80
Volume	N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. Our drug candidates target specific chemokines or chemoattractant receptors, thereby blocking the inflammatory response driven by that particular chemokine while leaving the rest of the immune system unaffected. Our goal is to discover, develop and commercialize therapeutics with distinct advantages over currently marketed therapies in our disease areas of focus, thereby maximizing ... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Jan 22, 2018*
[ChemoCentryx Announces Positive Overall Survival Results with CCR2 Inhibitor CCX872 for Locally Advanced/Metastatic Pancreatic Cancer](#)
- Jan 8, 2018*
[ChemoCentryx Strengthens Senior Executive Team with the Appointment of William Fairey as Executive Vice President and Chief Operating Officer](#)
- Jan 4, 2018*
[ChemoCentryx Secures up to \\$100 Million in New Capital Commitments](#)
- Jan 4, 2018*
[Avacopan Conditional Marketing Authorization Application Accepted for Regulatory Review by European Medicines Agency](#)
- Jan 3, 2018*
[ChemoCentryx to Present at the 36th Annual J.P. Morgan Healthcare Conference](#)

Financials [\[View all \]](#)

- Mar 14, 2017*
[Annual Report \(10-K\)](#)
- Apr 10, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Nov 7, 2017*
[Quarterly Report \(10-Q\)](#)
- Aug 8, 2017*
[Quarterly Report \(10-Q\)](#)
- May 10, 2017*
[Quarterly Report \(10-Q\)](#)